Pharmafile Logo

Foundayo

- PMLiVE

Eli Lilly names Ilya Yuffa as executive vice president and president, Lilly Global Markets

Patrik Jonsson, executive vice president and president, Lilly International, will retire at the end of 2026

- PMLiVE

MHRA approves new oral treatment for moderate-to-severe plaque psoriasis

Plaque psoriasis is an inflammatory condition that causes red, scaly and often itchy or painful patches of skin

- PMLiVE

New MHRA research published on needle-free Strep A vaccine

There is currently no licensed vaccine for Strep A, despite it causing hundreds of millions of infections globally

- PMLiVE

Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients

Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes

- PMLiVE

MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer

The treatment is for adults in combination with atezolizumab

- PMLiVE

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal

The deal focuses on addressing critical unmet medical needs

- PMLiVE

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links